preview

The Problem Of Pain Management

Good Essays

In their article, The problem of pain management: The makers of OxyContin play dirty, from the January 2015 edition of Harper’s magazine, Jonah Campbell and Simon Liem annotate a letter of request from Purdue Pharmaceutical to the Federal Drug Administration. Campbell, who is a research assistant at the McGill University Biomedical Ethics Unit and author of the book Food and Trembling, and Liem, a journalist, argue that Purdue Pharmaceuticals intentions with the letter of withdrawal are only to benefit themselves as a company and that Purdue’s drug formulation of OxyContin does not deter abuse, but the authors fail to back up several of their claims. The letter presented in the annotation consists of two pages and is dated March 19, 2013. The letter is addressed to Bob A. Rappaport, M.D., who appears from the letter to be the director of the FDA Center for Drug Evaluation and Research and written by Beth Connelly, a representative of Purdue. The heading on the letter reads as “Request withdrawal of approval of NDA 020553.” The pharmaceutical drug the letter is written in regards to is Purdue’s named brand OxyContin, a powerful narcotic pain medication. The letter is requesting that the FDA withdrawal approval of the drug due to the high risk of addiction or abuse. OxyContin, a derivative of the medication oxycodone, is an opioid pain medication available by prescription only and is often compared to the street drug heroin in regards to its chemical make up and

Get Access